Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Comment by Sonny7on Dec 08, 2019 10:15pm
164 Views
Post# 30434500

RE:RE:Perspective: Medtronic Dividend U$2.9 billion annual

RE:RE:Perspective: Medtronic Dividend U$2.9 billion annualIt appears that the JP Morgan Showcase is on from January 13th to the 15th in San Francisco.

Sernova will NOT be presenting, but WILL be meeting with various pharmaceutical companies to discuss business development ideas as the science moves forward. I would like to think that there COULD be news FDA trial news ahead of the Showcase to fuel the proverbial fires but no guarantees of that in my uneducated opinion, although timing in terms of the FDA trials could provide some optimism that fresh and positive news may become available ahead of the Showcase. That being the case, then Sernova’s bargaining power would place them in a strong position in terms of a collaboration agreement or buyout talks. 

my opinion
Bullboard Posts